TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2012. Net loss for the third quarter was $444,000, or $0.05 per diluted share. Results for the third quarter included financial expense of approximately $298,000 that resulted from the valuation of Tikcro’s holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. As of August 1, 2012, Tikcro’s note in BioCancell in the principal amount of $2.0 million was repaid in full, including accrued interest, in the gross amount of approximately $2.4 million.
